Cell therapy weekly: StemGenex receives warning letter from FDA over unapproved cell therapy and facility with “significant violations”
This week in cell therapy: HemaCare supplies starting materials for three FDA approved cell therapies and Mesoblast defends stem cell-based therapy for heart failure.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>